LOXL1-AS1 is a novel biomarker for predicting clinical progression and poor prognosis, and functions as tumor promoter to regulate osteosarcoma cell proliferation, migration, and invasion through PI3K-AKT pathway. Here, AKT1 is linked to neoplasm.